Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source reviews popular cosmeceutical ingredients for skin care, noting that while they are popular among consumers for anti-aging benefits, many lack robust clinical evidence for their efficacy and safety, as they are not regulated by the FDA.

This research suggests that recent discoveries of signaling pathways in androgenic alopecia may pave the way for targeted therapies, providing potential new treatment options beyond the current FDA-approved drugs, minoxidil and finasteride.

This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.

This review found that exosome use in aesthetic plastic surgery shows promise in areas like skin rejuvenation and hair restoration, with laboratory studies indicating enhanced outcomes, but clinical evidence remains largely anecdotal, and no exosome-based products have FDA approval.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.

This review paper discusses the effectiveness of repurposed drugs and potential novel therapies for treating COVID-19, highlighting remdesivir as the only FDA-approved medication and listing others with Emergency Use Authorization.

This review discusses the potential benefits of the Restolin Hair Supplement for hair growth and reports no clinical results, with the authors noting that the claims are not supported by FDA approval or clinical trials.

This review of female androgenetic alopecia treatments reports limited therapeutic options due to unclear pathogenesis, with minoxidil as the only FDA-approved treatment and adjuvant therapies under investigation.

This review discusses evidence from recent clinical trials showing inclisiran effectively lowers LDL cholesterol levels in patients with cardiovascular disease, leading to its use in the UK despite not being approved by the FDA.

This case report highlights the adverse effects of unmonitored bioidentical hormone replacement therapy, emphasizing the need for patient education about its safety and efficacy compared to FDA-regulated hormones.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

This review discusses current and emerging treatments for androgenic alopecia, noting that minoxidil and finasteride are the only FDA-approved options, while other methods lack comparable evidence of efficacy.

This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.

This study reported a significant increase in global online searches for finasteride and its possible sexual side effects, particularly after the FDA's 2012 warning.

This article discusses the importance of raising awareness about specific adverse drug reactions, methods of prevention, and the significance of reporting them to the FDA's MedWatch program, but reports no new clinical results.

This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

This study found that betibeglogene autotemcel significantly improved transfusion independence in 89% of patients with transfusion-dependent beta-thalassemia, although the high cost and manufacturing challenges may limit widespread adoption.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

This article suggests considering biologics to stabilize inflammation in moderate to severe folliculitis decalvans, although it reports no new clinical results.

In this case report, a 20-year-old male with folliculitis decalvans experienced remission of scalp lesions after treatment with doxycycline and topical ozenoxacin.

This study found that 5-α reductase inhibitors and neuropsychiatric medications were most frequently reported for erectile dysfunction in a national pharmacovigilance database from 2010 to 2020.

In this case study, the combination therapy of isotretinoin and rifampicin was reported to effectively improve symptoms in a 58-year-old female patient with folliculitis decalvans, suggesting this approach may warrant further investigation for treating this challenging condition.

In this report, a 54-year-old woman with familial dyskeratotic comedones showed slight improvement in skin lesions after topical retinoids and urea cream. This source also describes the first dermoscopic findings for this condition and reviews 21 previous cases.

Patients with Focal Dermal Hypoplasia often experience skin, nail, hair, and bone issues, and may benefit from calcium and vitamin D supplements.

This article discusses folliculitis decalvans as a cicatricial alopecia caused by a neutrophilic immune reaction to microbial biofilms, but it reports no new clinical results.

This report presents a unique case of folliculitis decalvans in two young sisters managed with low-dose isotretinoin and erythromycin, without specifying the treatment's success.